IDH1 and central nervous system cancer: We also found a higher proportion of patients with isocitrate dehydrogenase (IDH) wild-type, mesenchymal subtype, NON Glioma CpG island methylator phenotype (G-CIMP), and older age in the high-risk group, which are generally considered to be subtypes with worse prognosis.[4] Further, we compared the risk score between different subgroups in the TCGA training cohort.